ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 85 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $1,385,000 | 0.0% | 189,437 | 0.0% | 0.61% | +3.7% |
| Q4 2018 | $1,385,000 | -0.6% | 189,437 | +103.9% | 0.59% | +23.8% |
| Q3 2018 | $1,394,000 | -17.7% | 92,889 | +5.1% | 0.48% | -23.6% |
| Q2 2018 | $1,694,000 | +39.9% | 88,416 | +27.9% | 0.63% | +25.7% |
| Q1 2018 | $1,211,000 | +4.2% | 69,107 | +46.6% | 0.50% | -0.8% |
| Q4 2017 | $1,162,000 | -4.4% | 47,126 | 0.0% | 0.50% | -7.6% |
| Q3 2017 | $1,216,000 | +79.4% | 47,126 | +88.6% | 0.54% | +75.7% |
| Q2 2017 | $678,000 | -34.2% | 24,986 | -27.7% | 0.31% | -24.8% |
| Q1 2017 | $1,031,000 | – | 34,558 | – | 0.41% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |